Clinical trials are underway to investigate the treatment of adult-onset Still’s disease and NLRC4-related macrophage activation syndrome (inflammatory diseases associated with high plasma IL-18 levels) using IL-18BP [120,121,122] (ClinicalTrials.gov Identifier: NCT 02398435, NCT 03113760). The gene discussed is NLRC4; the disease is macrophage activation syndrome.